A costing study of bortezomib shows equivalence of its real‐world costs to conventional treatment

Thompson, Jane; Teh, Zoe; Chen, Yiyang; Gardiner, Joanne; Bednarz, Jana; Thompson, Greg; Lee, Cindy; Horvath, Noemi; Bardy, Peter; Yeung, David T.

doi:10.1111/bjh.16484

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Worldwide, cases have increased by 126% since 1990 with Australasia having the highest age-standardised incidence and death-rate followed by North America and Europe [ 26 ]. In Australia, myeloma has an estimated mean yearly cost per treatment per patient of approximately $25,000 [ 125 ]. Despite significant improvements in the 5-year survival rate (43% in the period of 2006–2010), the outcomes for older patients remain poor with a 19% 5-year survival rate in individuals aged 80-years or over [ 71 ].…”

Section: Introductionmentioning

confidence: 99%

Circulating biosignatures in multiple myeloma and their role in multidrug resistance

Krishnan¹,

Bebawy²

2023

Mol Cancer

View full text Add to dashboard Cite

A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance. This occurs when a tumour fails to reduce in size after treatment or when there is clinical relapse after an initial positive response to treatment. A unique and serious type of resistance is multidrug resistance (MDR). MDR causes the simultaneous cross resistance to unrelated drugs used in chemotherapy. MDR can be acquired through genetic alterations following drug exposure, or as discovered by us, through alternative pathways mediated by the transfer of functional MDR proteins and nucleic acids by extracellular vesicles (M Bebawy V Combes E Lee R Jaiswal J Gong A Bonhoure GE Grau, 23 9 1643 1649, 2009).Multiple myeloma is an incurable cancer of bone marrow plasma cells. Treatment involves high dose combination chemotherapy and patient response is unpredictable and variable due to the presence of multisite clonal tumour infiltrates. This clonal heterogeneity can contribute to the development of MDR. There is currently no approved clinical test for the minimally invasive testing of MDR in myeloma.Extracellular vesicles comprise a group of heterogeneous cell-derived membranous structures which include; exosomes, microparticles (microvesicles), migrasomes and apoptotic bodies. Extracellular vesicles serve an important role in cellular communication through the intercellular transfer of cellular protein, nucleic acid and lipid cargo. Of these, microparticles (MPs) originate from the cell plasma membrane and vary in size from 0.1-1um. We have previously shown that MPs confer MDR through the transfer of resistance proteins and nucleic acids. A test for the early detection of MDR would benefit clinical decision making, improve survival and support rational drug use. This review focuses on microparticles as novel clinical biomarkers for the detection of MDR in Myeloma and discusses their role in the therapeutic management of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%